Hualu Network Group 中文版
search
Investor Relation
Information transparency and trust in peers
Investor Relation
INTERIM REPORT
06
2025-06
Overseas Regulatory Announcement-Announcement on Ibuprofen Arginine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
Overseas Regulatory Announcement-Announcement on Ibuprofen Arginine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
06
2025-06
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
05
2025-06
Overseas Regulatory Announcement-Announcement on Isavuconazonium Sulfate for Injection Having Obtained Drug Registration Certificate
Overseas Regulatory Announcement-Announcement on Isavuconazonium Sulfate for Injection Having Obtained Drug Registration Certificate
02
2025-06
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025
22
2025-05
Overseas Regulatory Announcement-Announcement on Ibuprofen Suspension Drops Having Obtained Drug Registration Certificate
Overseas Regulatory Announcement-Announcement on Ibuprofen Suspension Drops Having Obtained Drug Registration Certificate
19
2025-05
Overseas Regulatory Announcement-Announcement on Icosapent Ethyl Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
Overseas Regulatory Announcement-Announcement on Icosapent Ethyl Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
14
2025-04
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
14
2025-04
Overseas Regulatory Announcement-Announcement on Aminophylline Tablets Passing the Generic Drugs Consistency Evaluation
14
2025-04
Announcement Notice of Board Meeting
02
2025-04
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2025
总条数: 30条
页
Copyright © Shandong Xinhua Pharmaceutical Co., Ltd
鲁ICP备09066031号
鲁公安备案号 3703900200041
(鲁)-非经营性-2015-0068
Technical Support:CR DIGITAL
Xinhua Pharmaceutical